Signal transduction targets in androgen-independent prostate cancer

被引:22
作者
Zhou, J [1 ]
Scholes, J [1 ]
Hsieh, JT [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX USA
关键词
prostate cancer; androgen-independent prostate cancer; signal transduction; growth factor; tumor suppressor;
D O I
10.1023/A:1015504015302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer (PCa) first manifests as an androgen-dependent disease. Thus, androgen-deprivation therapy is a standard regimen for patients with metastatic PCa. Despite the initial success of androgen-deprivation therapy, PCa inevitably progresses from being androgen dependent (AD) to androgen independent (AI), and this marks the poor prognosis of this disease. Relapse of AIPCa becomes life threatening and accounts for the majority of mortality of PCa patients. Currently, no effective therapy is available for controlling AIPCa. Therefore, the challenge in providing a new intervention is to understand the fundamental changes that occur in AIPCa. Increasing evidence indicates that, under androgen-deprived milieu, several signal networks elicited by peptide growth factors dictate the AI phenotype of PCa. This review covers the latest studies investigating the potential involvement of autocrine growth factors in cell proliferation, survival, metastasis, and the reciprocal interaction with the androgen receptor pathway. In addition, loss of the negative feedback mechanism of the signal cascade further amplifies the effect of growth factors, and thus contributes significantly to the onset of AIPCa. The understanding of the signal target(s) in AIPCa should provide the new markers for prognosis and a new strategy for prevention and therapy.
引用
收藏
页码:351 / 362
页数:12
相关论文
共 132 条
[91]  
Putz T, 1999, CANCER RES, V59, P227
[92]  
Rajan R, 1996, PROSTATE, V28, P1, DOI 10.1002/(SICI)1097-0045(199601)28:1<1::AID-PROS1>3.0.CO
[93]  
2-L
[94]   Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway [J].
Ramaswamy, S ;
Nakamura, N ;
Vazquez, F ;
Batt, DB ;
Perera, S ;
Roberts, TM ;
Sellers, WR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) :2110-2115
[95]  
Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO
[96]  
2-C
[97]   PROGRESSION OF ANDROGEN-SENSITIVE MOUSE-TUMOR (SHIONOGI CARCINOMA-115) TO ANDROGEN-INSENSITIVE TUMOR AFTER LONG-TERM REMOVAL OF TESTOSTERONE [J].
SATO, N ;
WATABE, Y ;
SUZUKI, H ;
SHIMAZAKI, J .
JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (12) :1300-1308
[98]  
Scher HI, 1995, CLIN CANCER RES, V1, P545
[99]   SH2/SH3 SIGNALING PROTEINS [J].
SCHLESSINGER, J .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1994, 4 (01) :25-30
[100]   Development of anticancer drugs targeting the MAP kinase pathway [J].
Sebolt-Leopold, JS .
ONCOGENE, 2000, 19 (56) :6594-6599